Prophylactic CD45RA-depleted DLI After Haploidentical Transplantation/RIC

Phase 1

Recruiting

• Conditions: Hematologic Malignancy; Haplo-identical Stem Cell Transplantation
• Interventions: Other: CD45RAneg cells, prepared from mononuclear cell leukapheresis by CliniMACS® technology

• Registration Number: NCT05066412
• Lead Sponsor: University Hospital, Geneva

Brief Summary

To assess safety of prophylactic escaladed dose of T naïve depleted (CD45RA depleted donor lymphocyte infusion, in patients with malignant hemopathie who received an allogeneic stem cell transplant from an haplo-identical donor, after a reduced intensity conditionning regiment.

Detailed Description

Primary Objective is to determine whether the administration of prophylactic CD45RAneg (CD45RAneg) memory/effector T lymphocytes is feasible and safe in the early post-transplant period for patients with haploidentical transplant and RIC conditioning.

Donor lymphocytes are isolated from the original donor by non-mobilized mononuclear cell leukapheresis. Repetitive intravenous infusions (up to 3) of escalating doses of CD45RAneg cells, prepared from the leukapheresis by CliniMACS® technology (CD45RA-depletion), storage in vapor nitrogen.

Escalating doses of CD45RAneg cells, for patients with haploidentical graft, intervals of 6-8 weeks, if GvHD is absent starting ≥ 4 weeks from the day of transplantation.

Study Timeline

• Study First Submitted: 2021-07-09
• Study First Submitted QC: 2021-10-01
• Study First Posted: 2021-10-04
• Study Start: 2024-11-26
• Status Verified: 2025-01
• Last Update Submitted: 2025-02-10
• Last Update Posted: 2025-02-13
• Primary Completion: 2026-06-02
• Study Completion: 2026-12-02

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 12

Inclusion Criteria

• Patients who received a stem cell graft from a haploidentical donor after RIC for hematologic malignancies
• Written informed consent of patient and donor obtained

Exclusion Criteria

• Participant taking Prednisone (or equivalent steroid)
• Participant taking Prednisone (or equivalent steroid)
• Participant taking Mycophenolate Mofetil
• Participant taking Cyclosporine/tacrolimus at therapeutic blood levels
• Progressive hematologic malignancy before transplant
• Second allogeneic transplant
• Acute GvHD ≥ grade 2
• Chronic moderate or severe GvHD (NIH consensus criteria)
• Hematologic or molecular relapse of the primary malignancy requiring chemotherapy or unmanipulated DLI (receiving prophylactic antileukemic agent, eg TKI, is not an exclusion criteria)
• Donor aberrant CD45RA expression due to a polymorphism in CD45 gene
• Participation in another interventional clinical trial within 30 days prior to inclusion
• Pregnant or nursing women. Sexually active women with childbearing potential as well as sexually active male patients who are unwilling to use an effective method of contraception during participation in the study from time of inclusion until 2 months after last dose of CD45RAneg DLI infusion
• Inability to follow the procedures of the study, including, but not limited to, language problems, psychological disorders, dementia

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Arm 1	CD45RAneg cells, prepared from mononuclear cell leukapheresis by CliniMACS® technology	Prophylactic CD45RA-depleted DLI

Primary Outcome Measures

Name	Time	Method
acute transfusion reaction (CTCAE ≥ 2)	24 hours after each CD45RA neg DLI infusion	acute transfusion reaction after each DLI infusion (CTCAE ≥ 2)
acute GvHD grade II-IV	within 8 weeks after each CD45RAneg DLI infusion	acute GvHD grade II-IV measured with MAGIC score

Trial Locations

Locations (1)

HUG; 🇨🇭 Geneva, Switzerland